ClinicalTrials.gg
RecruitingNCT05042375Updated Nov 17, 2022

A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

A Phase 3 interventional study of camrelizumab + famitinib and pembrolizumab in Non-small Cell Lung Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Recruiting at 80 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-11-17.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 10 months ago, but the record still lists the study as recruiting.
  • Started Sep 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 27 studies testing camrelizumab in Carcinoma, Non-Small-Cell Lung — 6 open to participants now, 7 under way, 1 of them phase 3. camrelizumab · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
2nd of 27
450 · median 58
Started
2022
with 3 others
Phase 3
5 of 27
1 open now
Registered
21st of 27
by date
Lead sponsor
7 of 27
Jiangsu HengRui Medicine Co., Ltd.

Among the 27 studies testing camrelizumab in Carcinoma, Non-Small-Cell Lung, this one is the 2nd largest by planned enrollment, is one of 4 that started in 2022, is one of 5 in phase 3, and was the 21st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

6 of the 27 studies testing camrelizumab in Carcinoma, Non-Small-Cell Lung are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

About camrelizumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing camrelizumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the efficacy, and safety of camrelizumab combined with famitinib malate vs. pembrolizumab in treatment naïve subjects with programmed death-ligand 1(PD-L1)-positive recurrent or metastatic non-small cell lung cancer (NSCLC).

03

Conditions studied

  • Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have a or cytologically confirmed diagnosis of NSCLC (stage IV according to the TNM staging criteria [8th edition] published by the International Association for the Study of Lung Cancer [IASLC]), or NSCLC that recurs after curable surgery, radiotherapy, or radiochemotherapy.
  2. Have based on v1.1.
  3. PS score: 0-1.
  4. Have a of at least 3 months.
  5. Non-surgically sterilized female subjects or women of must be negative for a serum pregnancy test within 3 days prior to the first dose and must be non-lactating. Female subjects of childbearing potential and male subjects with partners of childbearing potential must agree to take highly effective measures during the study period and within 6 months after the last dose of study drugs.
  6. Have voluntarily agreed to participate by giving written for the study, have good compliance, and cooperate with follow-up visits.

Exclusion criteria

Exclusion Criteria:

  1. Accompanied with EGFR activating mutation, ALK fusion gene positive or ROS1 mutation.
  2. Have uncontrolled clinically symptomatic pleural effusion, pericardial effusion, or ascites.
  3. Have known history of prior in the past 3 years.
  4. Have had an allogeneic tissue/solid organ transplant.
  5. Have active pulmonary tuberculosis.
  6. Have clinical symptoms of the heart or heart diseases that are not well controlled.
  7. Have hypertension which cannot be well controlled by antihypertensives
  8. Urinalysis has indicated that the urine protein is ≥ ++ and quantitative test of urine protein has confirmed that the 24-h urine protein is > 1.0 g.
  9. Have a thrombosis tendency or are currently receiving thrombolysis/anticoagulation therapy.
  10. Have received major surgery within 4 weeks prior to randomization; or palliative radiotherapy within 2 weeks prior to randomization; or have not recovered from the toxicities and/or complications of previous interventions to Grade ≤ 1.
  11. Have known history of arterial/venous thrombosis within 6 months prior to randomization, such as cerebrovascular accidents, deep vein thrombosis and pulmonary embolism.
  12. Have received prior therapy with /PD-L1 monoclonal antibodies, anti-CTLA-4 monoclonal antibodies, or small molecule VEGFR inhibitors.
  13. Have known allergies to other monoclonal antibodies or any component of famitinib.
  14. Are currently participating and receiving study therapy or have participated in a study and received the last dose of study drug within 4 weeks (or 5 half-lives of the study drug) prior to randomization.
  15. Have other potential factors that may affect the study results or result in the premature discontinuation as determined by the investigator, such as alcoholism, drug abuse, substance abuse, other serious diseases (including mental illness) requiring concomitant treatment, serious laboratory abnormalities, or family or social factors that could affect the safety of medication.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
450 participants (estimated)

Study arms

  • Experimental
    camrelizumab + famitinib

    Drug: camrelizumab + famitinib

  • Experimental
    pembrolizumab

    Drug: pembrolizumab

  • Experimental
    camrelizumab

    Drug: camrelizumab

Interventions

06

What researchers measure

Primary outcomes

  1. PFS assessed by BIRC

    Progression-Free-Survival, defined as the time from randomization to the first occurrence of disease progression as determined by IRC with use of RECIST v1.1 or death from any cause, whichever occurs first.

    Time frame: up to 3 years

Secondary outcomes

  1. PFS assessed by investigator

    Progression-Free-Survival

    Time frame: up to 3 years

  2. ORR

    Objective Response Rate, determined using RECIST v1.1 criteria, defined as best overall response (CR or PR) across all assessment time points

    Time frame: up to 3 years

  3. DCR

    Disease Control Rate, determined using RECIST v1.1 criteria

    Time frame: up to 3 years

  4. DoR

    Duration of Response, determined using RECIST v1.1 criteria

    Time frame: up to 3 years

  5. TTF

    Time to Treatment Failure, defined as the time from randomization to treatment discontinuation.

    Time frame: up to 3 years

  6. AEs+SAEs

    Adverse Events and Serious Adverse Events

    Time frame: from the first drug administration to within 90 days for the last SHR-1210 dose

  7. OS

    OS is the time interval from the date of randomization to death due to any reason or lost of follow-up

    Time frame: up to 4 years

07

Study locations

20 of 80 sites recruiting
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, Anhui 233000, China
    Not yet recruiting
    • Chengling Zhao · Principal investigator
  • Anhui Chest Hospital
    Hefei, Anhui 230000, China
    Not yet recruiting
    • Haowei Fang · Principal investigator
  • Anhui Provincial Cancer Hospital
    Hefei, Anhui 230000, China
    Not yet recruiting
    • Zhihong Zhang · Principal investigator
  • Anhui Provincial Hospital
    Hefei, Anhui 230000, China
    Not yet recruiting
    • Xinghua Han · Principal investigator
  • The First Affiliated Hospital Of Anhui Medical University
    Hefei, Anhui 230000, China
    Not yet recruiting
    • Yingying Du · Principal investigator
  • Beijing Cancer Hospital
    Beijing, Beijing 100000, China
    Not yet recruiting
    • Jian Fang · Principal investigator
  • Beijing Chest Hospital,Capital Medical University
    Beijing, Beijing 100000, China
    Not yet recruiting
    • Tongmei Zhang · Principal investigator
  • Peking University Third Hospital
    Beijing, Beijing 100000, China
    Recruiting
    • Baoshan Cao · Principal investigator
  • ChongQing University Cancer Hospital
    Chongqing, Chongqing 400000, China
    Recruiting
    • Luchun LI · Principal investigator
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian 350000, China
    Not yet recruiting
    • Jinhuo Lai · Principal investigator
  • Fujian Provincial Cancer Hospital
    Fuzhou, Fujian 350000, China
    Not yet recruiting
    • Zhiyong He · Principal investigator
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian 361000, China
    Not yet recruiting
    • Qihong Zhuang · Principal investigator
  • The Second Affiliated Hospital of Xiamen Medical College
    Xiamen, Fujian 361000, China
    Recruiting
    • Hui Yang · Principal investigator
  • The People's Hospital of Gaozhou
    Gaozhou, Guangdong 525200, China
    Not yet recruiting
    • Wanli Lin · Principal investigator
  • Affiliated Cancer Hospital and Institute of Guangzhou Medical University
    Guangzhou, Guangdong 510000, China
    Not yet recruiting
    • Jian Wang · Principal investigator
  • The First Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 510000, China
    Not yet recruiting
    • Chengzhi Zhou · Principal investigator
  • The First Affiliated Hospital of Guangzhou University of Chinese Medicine
    Guangzhou, Guangdong 510000, China
    Not yet recruiting
    • Lizhu Lin · Principal investigator
  • Meizhou People's Hospital (Huangtang Hospital)
    Meizhou, Guangdong 514000, China
    Not yet recruiting
    • Guowu Wu · Principal investigator
  • Shantou Central Hospital
    Shantou, Guangdong 515000, China
    Not yet recruiting
    • Xunyan Liu · Principal investigator
  • Affiliated Hospital of Guangdong Medical University
    Zhanjiang, Guangdong 524000, China
    Not yet recruiting
    • Hualin Chen · Principal investigator
  • Affiliated Hospital of Guilin Medical University
    Guilin, Guangxi 541000, China
    Not yet recruiting
    • Mafei Kang · Principal investigator
  • Guangxi Medical University Affiliated Tumor Hospital
    Nanning, Guangxi 530000, China
    Not yet recruiting
    • Aiping Zeng · Principal investigator
  • The First Affiliated Hospital of Guangxi Medical University
    Nanning, Guangxi 530000, China
    Not yet recruiting
    • Zhiyi He · Principal investigator
  • Affiliated Hospital of Zunyi Medical University
    Zunyi, Guizhou 563000, China
    Not yet recruiting
    • Liang Zhou · Principal investigator
  • Hainan General Hospital
    Haikou, Hainan 570100, China
    Not yet recruiting
    • Yongxing Chen · Principal investigator
  • The Fourth Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050000, China
    Not yet recruiting
    • Jun Wang · Principal investigator
  • North China University Of Science And Technology Affiliated Hospital
    Tangshan, Hebei 063000, China
    Not yet recruiting
    • Guogui Sun · Principal investigator
  • Xingtai People's Hospital
    Xingtai, Hebei 054000, China
    Not yet recruiting
    • Yonghui Di · Principal investigator
  • Haerbin Medical University Cancer Hospital
    Ha'erbin, Heilongjiang 150000, China
    Not yet recruiting
    • Yan Wang · Principal investigator
  • Anyang Cancer Hospital
    Anyang, Henan 455000, China
    Recruiting
    • Yonggui Hong · Principal investigator
  • The First Affiliated Hosptial of Henan University of Science & Technology
    Luoyang, Henan 471000, China
    Recruiting
    • Jun Yao · Principal investigator
  • Henan Cancer Hospital
    Zhengzhou, Henan 450000, China
    Not yet recruiting
    • Qiming Wang · Principal investigator
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450000, China
    Recruiting
    • Guojun Zhang · Principal investigator
  • Shiyan Taihe Hospital
    Shiyan, Hubei 442000, China
    Not yet recruiting
    • Meifang Wang · Principal investigator
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei 430000, China
    Not yet recruiting
    • Xiaorong Dong · Principal investigator
  • Xiangyang Central Hospital
    Xiangyang, Hubei 441000, China
    Recruiting
    • Tienan Yi · Principal investigator
  • Army Medical Center of PLA
    Changsha, Hunan 410000, China
    Recruiting
    • Xuewen Liu · Principal investigator
  • Hunan Cancer Hospital-Thoracic Medicine Department I
    Changsha, Hunan 410000, China
    Recruiting
    • Yongzhong Luo · Principal investigator
  • Hunan Cancer Hospital-Thoracic Medicine Department Ⅱ
    Changsha, Hunan 410000, China
    Recruiting
    • Lin Wu · Principal investigator
  • Xiangya Hospital Central South University
    Changsha, Hunan 410000, China
    Not yet recruiting
    • Huaping Yang · Principal investigator
  • Shaoyang Central Hospital
    Shaoyang, Hunan 422000, China
    Recruiting
    • Xinfu Liu · Principal investigator
  • Zhuzhou Central Hospital
    Zhuzhou, Hunan 412000, China
    Not yet recruiting
    • Bo Qiu · Principal investigator
  • Affiliated Drum Tower Hospital, Medical School of Nanjing University
    Nanjing, Jiangsu 210000, China
    Not yet recruiting
    • Yongsheng Wang · Principal investigator
  • Zhongda Hospital Southeast University
    Nanjing, Jiangsu 210000, China
    Recruiting
    • Ruifeng Zhang · Principal investigator
  • Nantong Tumor Hospital
    Nantong, Jiangsu 226000, China
    Not yet recruiting
    • Junguo Lu · Principal investigator
  • Affiliated Hospital of JiangNan University
    Wuxi, Jiangsu 214000, China
    Recruiting
    • Xiaoping Chen · Principal investigator
  • The Affiliated Hospital of Xuzhou Medical University
    Xuzhou, Jiangsu 221000, China
    Not yet recruiting
    • Bi Chen · Principal investigator
  • Northern Jiangsu People's Hospital
    Yangzhou, Jiangsu 225000, China
    Recruiting
    • Xingxiang Xu · Principal investigator
  • First Affiliated Hospital of Gannan Medical University
    Ganzhou, Jiangxi 341000, China
    Not yet recruiting
    • Huaqiu Shi · Principal investigator
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330000, China
    Recruiting
    • Fei Xu · Principal investigator
  • The Second Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330000, China
    Recruiting
    • Anwen Liu · Principal investigator
  • Liaoning Cancer Hospital
    Shenyang, Liaoning 110000, China
    Not yet recruiting
    • Jinghui Bai · Principal investigator
  • Shengjing Hospital Affiliated to China Medical University
    Shenyang, Liaoning 110000, China
    Not yet recruiting
    • Wei Zheng · Principal investigator
  • The First Hospital of China Medical University
    Shenyang, Liaoning 110000, China
    Not yet recruiting
    • Bo Jin · Principal investigator
  • Chifeng City Hospital
    Chifeng, Neimenggu 024000, China
    Not yet recruiting
    • Minghui Zhang · Principal investigator
  • The Affiliated Hospital of Inner Mongolia Medical University
    Hohhot, Neimenggu 010000, China
    Not yet recruiting
    • Qun Hu · Principal investigator
  • Qilu Hospital of Shandong University
    Jinan, Shandong 250000, China
    Not yet recruiting
    • Yufeng Cheng · Principal investigator
  • Shandong Cancer Hospital&Institute
    Jinan, Shandong 250000, China
    Not yet recruiting
    • Xiqin Zhang · Principal investigator
  • The Affiliated of Qingdao University
    Qingdao, Shandong 266000, China
    Not yet recruiting
    • Jing Wang · Principal investigator
  • LinYi Cancer Hospital
    Linyi, Shangdong 276000, China
    Not yet recruiting
    • Jianhua Shi · Principal investigator
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai 200000, China
    Not yet recruiting
    • Si Sun · Principal investigator
  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai 200000, China
    Not yet recruiting
    • Min Zhou · Principal investigator
  • Shanghai Chest Hospital
    Shanghai, Shanghai 200000, China
    Not yet recruiting
    • Hua Zhong · Principal investigator
  • Shanghai Pulmonary Hospital
    Shanghai, Shanghai 200000, China
    Recruiting
    • Caicun Zhou · Principal investigator
  • Baoji Central Hospital
    Baoji, Shanxi 721000, China
    Not yet recruiting
    • Yaning Zhao · Principal investigator
  • Changzhi People's Hospital
    Changzhi, Shanxi 046000, China
    Not yet recruiting
    • Jun Zhao · Principal investigator
  • General Hospital of TISCO
    Taiyuan, Shanxi 030000, China
    Not yet recruiting
    • Weihua Jia · Principal investigator
  • Shanxi Bethune Hospital
    Taiyuan, Shanxi 030000, China
    Not yet recruiting
    • Qi Mei · Principal investigator
  • Shanxi Provincial Cancer Hospital
    Taiyuan, Shanxi 030000, China
    Recruiting
    • Weihua Yang · Principal investigator
  • The Second Affiliated Hospital of Air Force Military University Tangdu Hospital
    Xi'an, Shanxi 710000, China
    Recruiting
    • Haichuan Su · Principal investigator
  • Sichuan Cancer Hospital
    Chengdu, Sichuan 610000, China
    Not yet recruiting
    • Wenxiu Yao · Principal investigator
  • The Affiliated Hospital of Southwest Medical University
    Luzhou, Sichuan 646000, China
    Not yet recruiting
    • Peirong Ren · Principal investigator
  • Mianyang Central Hospital
    Mianyang, Sichuan 621000, China
    Not yet recruiting
    • Weiguo Xu · Principal investigator
  • Yibin Second People's Hospital
    Yibin, Sichuan 644000, China
    Not yet recruiting
    • Shanbing Wang · Principal investigator
  • Tianjin Medical University Cancer Institute & Hospital
    Tianjin, Tianjin 300000, China
    Recruiting
    • Dingzhi Huang · Principal investigator
  • Yunnan Cancer Hospital
    Kunming, Yunnan 650000, China
    Not yet recruiting
    • Yunchao Huang · Principal investigator
  • Hangzhou Cancer Hospital
    Hangzhou, Zhejiang 310000, China
    Not yet recruiting
    • Xueqin Chen · Principal investigator
  • The First Affiliated Hospital, College of Medicine, Zhejiang University of Medicine
    Hangzhou, Zhejiang 310000, China
    Not yet recruiting
    • Jianya Zhou · Principal investigator
  • The Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310000, China
    Not yet recruiting
    • Wen Li · Principal investigator
  • ZheJiang Cancer Hospital
    Hangzhou, Zhejiang 310000, China
    Not yet recruiting
    • Yun Fan · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Dec 2023, 15 months after the start.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 15 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2021
First posted
Sep 13, 2021
StartActual
Sep 8, 2022
Primary completionEst.
Dec 31, 2023
CompletionEst.
Dec 31, 2025
Last update
Nov 17, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05042375
Responsible party
Sponsor
First posted
Sep 13, 2021
Start date
Sep 8, 2022
Primary completion
Dec 31, 2023 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Nov 17, 2022

Study contacts

weixia Li, M.M
Contact
Weixia.li@hengrui.com
+86-15005136260

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Camrelizumab · Famitinib

Start the discussion